Cargando…

The use of electronic alerts in primary care computer systems to identify the over-prescription of short-acting beta(2)-agonists in people with asthma: a protocol for a systematic review

Detalles Bibliográficos
Autores principales:	McKibben, Shauna, Bush, Andy, Thomas, Mike, Griffiths, Chris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5435095/ https://www.ncbi.nlm.nih.gov/pubmed/28446776 http://dx.doi.org/10.1038/s41533-017-0033-y

Ejemplares similares

The use of electronic alerts in primary care computer systems to identify the excessive prescription of short-acting beta(2)-agonists for people with asthma: a systematic review
por: McKibben, Shauna, et al.
Publicado: (2018)

“Tossing a coin:” defining the excessive use of short-acting beta(2)-agonists in asthma—the views of general practitioners and asthma experts in primary and secondary care
por: McKibben, Shauna, et al.
Publicado: (2018)

Author Correction: “Tossing a coin:” defining the excessive use of short-acting beta2-agonists in asthma—the views of general practitioners and asthma experts in primary and secondary care
por: McKibben, Shauna, et al.
Publicado: (2019)

Over-prescription of short-acting β(2)-agonists and asthma management in the Gulf region: a multicountry observational study
por: Alzaabi, Ashraf, et al.
Publicado: (2022)

Over-prescription of short-acting β(2)-agonists for asthma in South Africa: Results from the SABINA III study
por: Smith, C, et al.
Publicado: (2022)

Prescription of oral short-acting beta 2-agonist for asthma in non-resource poor settings: A national study in Malaysia
por: Chin, May Chien, et al.
Publicado: (2017)

Asthma prescribing, ethnicity and risk of hospital admission: an analysis of 35,864 linked primary and secondary care records in East London
por: Hull, Sally A, et al.
Publicado: (2016)

Reducing short-acting beta-agonist overprescribing in asthma: lessons from a quality-improvement prescribing project in East London
por: De Simoni, Anna, et al.
Publicado: (2022)

Short-acting beta-2 agonist prescription patterns and clinical outcomes in Chinese patients with asthma: an observational study in mainland China for the SABINA programme
por: Bao, Wuping, et al.
Publicado: (2022)

Evaluation of short-acting Beta-2-agonist prescriptions and associated clinical outcomes: Findings from the SABA use IN Asthma (SABINA) study in Asia
por: Wang, Hao-Chien, et al.
Publicado: (2023)

Paradoxical Bronchoconstriction with Short-Acting Beta Agonist
por: Magee, Jared S., et al.
Publicado: (2018)

Over-the-counter use of short-acting beta-2 agonists: a systematic review
por: Loh, Zhe Chi, et al.
Publicado: (2023)

Short-acting β(2)-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III
por: Yorgancıoğlu, Arzu, et al.
Publicado: (2022)

Short-acting β(2)-agonist prescription patterns for asthma management in the SABINA III primary care cohort
por: Price, David, et al.
Publicado: (2022)

Factors Associated with Failure of Intermittent Nebulization with Short-Acting Beta-Agonists in Children with Severe Asthma Exacerbation
por: Kulalert, Prapasri, et al.
Publicado: (2020)

Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma
por: Kaye, Leanne, et al.
Publicado: (2022)

Prediction of short-acting beta-agonist usage in patients with asthma using temporal-convolutional neural networks
por: Hirons, Nicholas, et al.
Publicado: (2023)

Assessment of the safety of long-acting β(2)-agonists in routine asthma care: the ASTRO-LAB protocol
por: Van Ganse, Eric, et al.
Publicado: (2015)

Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany
por: Worth, Heinrich, et al.
Publicado: (2021)

Short-Acting Beta2-Agonist Use in Asthma in Korea: A 10-Year Population-Based Study
por: Lee, Hyun, et al.
Publicado: (2021)

Characteristics of patients with asthma overprescribed short-acting beta-agonist (SABA) reliever inhalers stratified by blood eosinophil count in North East London: a cross-sectional observational study
por: Pfeffer, Paul, et al.
Publicado: (2023)

Real-Life Patterns of Exacerbations While on Inhaled Corticosteroids and Long-Acting Beta Agonists for Asthma over 15 Years
por: McGeachie, Michael J., et al.
Publicado: (2020)

Short-acting β(2)-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study
por: Bateman, Eric D., et al.
Publicado: (2022)

Loss of Asthma Control in Pediatric Patients after Discontinuation of Long-Acting Beta-Agonists
por: R. O'Hagan, Adrian, et al.
Publicado: (2012)

Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid
por: Dreher, Michael, et al.
Publicado: (2018)

A Cross-Sectional Study on Prescription Patterns of Short-Acting β(2)-Agonists in Patients with Asthma: Results from the SABINA III Colombia Cohort
por: Pedrozo-Pupo, John Carlos, et al.
Publicado: (2022)

Over-prescription of short-acting β(2)-agonists remains a serious health concern in Kenya: results from the SABINA III study
por: Chakaya, Jeremiah, et al.
Publicado: (2023)

Developing a Smartphone Application That Promotes Responsible Short-Acting Beta2-Agonist Use in People with Asthma: A Participatory Design
por: van den Berg, Liselot N., et al.
Publicado: (2022)

SABINA: An Overview of Short-Acting β(2)-Agonist Use in Asthma in European Countries
por: Janson, Christer, et al.
Publicado: (2020)

The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan
por: Wang, Cheng-Yi, et al.
Publicado: (2021)

It is time to end our love affair with short-acting β(2)-agonists in asthma
por: Crooks, Michael G., et al.
Publicado: (2022)

Short-acting β(2)-agonists and exacerbations in children with asthma in England: SABINA Junior
por: Morgan, Ann, et al.
Publicado: (2023)

Overuse of Short-Acting Beta-2 Agonists (SABAs) in Elite Athletes: Hypotheses to Explain It
por: Vertadier, Nicolas, et al.
Publicado: (2022)

Global Initiative for Asthma 2021: Asthma in Preschool Children and Short-Acting β(2)-Agonist–Only Treatment
por: Baraldi, Eugenio, et al.
Publicado: (2022)

Understanding reliever overuse in patients purchasing over-the-counter short-acting beta(2) agonists: an Australian community pharmacy-based survey
por: Azzi, Elizabeth A, et al.
Publicado: (2019)

Symptom-driven inhaled corticosteroid/long-acting beta-agonist therapy for adult patients with asthma who are non-adherent to daily maintenance inhalers: a study protocol for a pragmatic randomized controlled trial
por: Krings, James G., et al.
Publicado: (2022)

Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma–COPD overlap syndrome
por: Lee, Suh-Young, et al.
Publicado: (2016)

Is overreliance on short-acting β(2)-agonists associated with health risks in the older asthma population?
por: To, Teresa, et al.
Publicado: (2022)

It is time to end our love affair with short-acting β(2)-agonists in asthma? Yes
por: Nannini, Luis J.
Publicado: (2023)

RETRACTED ARTICLE: Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?
por: Postma, Dirkje S., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_qoo63ndp74b1lkplak0pp7pjqo